Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome
Hannah Ceuleers, Nikita Hanning, Jelena Heirbaut et al. · British Journal of Pharmacology · 2018
BACKGROUND AND PURPOSE: Serine proteases have been re suggested as important mediators of visceral pain. We investigated their effect by using newly developed serine protease inhibitors with a well-characterized inhibitory profile in a rat model of post-inflammatory irritable bowel syndrome (IBS). EXPERIMENTAL APPROACH: Colitis was induced in rats receiving intrarectal trinitrobenzenesulphonic acid; controls received 0.9% NaCl. Colonoscopies were performed on day 3, to confirm colitis, and later until mucosal healing. Visceral hypersensitivity was quantified by visceromotor responses (VMRs) to colorectal distension, 30 min after i.p. injection of the serine protease inhibitors nafamostat, UAMC-00050 or UAMC-01162. Serine proteases, protease-activated receptors (PARs) and TRP channels were quantified by qPCR and immunohistochemistry. Proteolytic activity was characterized using fluorogenic substrates. KEY RESULTS: VMR was significantly elevated in post-colitis rats. Nafamostat normalized VMRs at the lowest dose tested. UAMC-00050 and UAMC-01162 significantly decreased VMR dose-dependently. Expression of mRNA for tryptase-αβ-1and PAR4, and tryptase immunoreactivity was significantly increased in the colon of post-colitis animals. Trypsin-like activity was also significantly increased in the colon but not in the faeces. PAR2 and TRPA1 immunoreactivity co-localized with CGRP-positive nerve fibres in control and post-colitis animals. CONCLUSIONS AND IMPLICATIONS: Increased expression of serine proteases and activity together with increased expression of downstream molecules at the colonic and DRG level and in CGRP-positive sensory nerve fibres imply a role for serine proteases in post-inflammatory visceral hypersensitivity. Our results support further investigation of serine protease inhibitors as an interesting treatment strategy for IBS-related visceral pain.
Cited by 49 works. doi:10.1111/bph.14396 Open-access PDF
Authors
- Hannah Ceuleers
- Nikita Hanning
- Jelena Heirbaut
- Samuel Van Remoortel
- Jurgen Joossens
- Pieter Van der Veken
- Sven Francque
- Michelle De bruyn
- Anne‐Marie Lambeir
- Joris G. De Man
- Jean‐Pierre Timmermans
- Koen Augustyns
- Ingrid De Meester
- Benedicte Y. De Winter
References
- The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
- Animal research: Reporting in vivo experiments: The ARRIVE guidelines
- Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
- Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome
- The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
- The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects
- Implementing guidelines on reporting research using animals ( ARRIVE etc.): new requirements for publication in BJP
- Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
- Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat
- Irritable Bowel Syndrome